Introduction {#sec1}
============

Osteoarthritis (OA), a complex and multifactorial disease, is the most common degenerative arthritis characterized by the degeneration of articular cartilage with joint space narrowing, osteophyte formation, and subcondral sclerosis resulting in pain and joint stiffness \[[@B1],[@B2]\]. Accumulating evidence suggests that aging, genetic predisposition, obesity, inflammation, and excessive mechanical loading predispose to OA development \[[@B3]\]. Epidemiological studies suggested that OA has a strong genetic component. A number of candidate genes, such as encoding collagens (particularly for type II collagen) and other structural proteins of the extracellular cartilage matrix, have been deemed to susceptibility loci for primary OA \[[@B4],[@B5]\].

Smad family member 3 (SMAD3) locates on chromosomes 15q21-22. SMAD3 is a key intracellular messenger of the transforming growth factor-β (TGF-β) signaling pathway, which is an important growth factor to the integrity of articular cartilage \[[@B6],[@B7]\]. TGF-β stimulates proteoglycan and type II collagen synthesis, can down-regulate cartilage-degrading enzymes, and is able to counteract interleukin-1-induced suppression of proteoglycan synthesis \[[@B8]\]. Increasing evidence suggests that TGF-β takes important part in the pathogenesis and progression of OA by functioning as key regulators in bone formation, remodeling, and maintenance \[[@B6],[@B9],[@B10]\]. Therefore, it is reasonable to hypothesize that the *SMAD3* may be a candidate gene for OA susceptibility.

Recently, several studies explored the relationship between *SMAD3* gene rs12901499 polymorphism and OA risk \[[@B11]\]. However, the results of these studies were conflicting and inconclusive because of the clinical heterogeneity, different ethnic populations, and small sample sizes. To precisely elucidate the genetic role for *SMAD3* gene rs12901499 polymorphism in the development of OA, we performed a comprehensive meta-analysis to clarify the association between this single nucleotide polymorphism (SNP) and OA risk.

Materials and methods {#sec2}
=====================

Identification of eligible studies and data extraction {#sec2-1}
------------------------------------------------------

We performed a comprehensive literature search throughout PubMed, Embase, and CNKI databases to retrieve the genetic association studies of OA. The following terms were used in our searching strategies: "Smad family member 3", "SMAD3", "SNP", "polymorphism", "variant", "osteoarthritis", "OA" to identify the publications reporting on *SMAD3* gene rs12901499 polymorphism and OA risk. Additional usable data were obtained by hand searching the bibliographies of genetic association studies on the subject in this analysis. We used no restrictions on the number of samples and language to minimize publications bias. All studies were carefully selected and were up to date as of March 1, 2018. The inclusion criteria for studies were as follows: (1) studies that evaluated the association between *SMAD3* gene rs12901499 polymorphism and OA, (2) studied on human beings, and (3) contained genotype data for the calculation of odds ratios (ORs) and 95% confidence intervals (CIs). The following information was extracted from each study: author, year of publication, ethnicity based on the continent of origin of the study population, type of OA, source of controls (SOC), numbers of cases and controls, and the genotype methods.

Statistical analysis {#sec2-2}
--------------------

ORs and 95%CIs were used to evaluate the strength of correlation between *SMAD3* gene rs12901499 polymorphism and OA risk. Stratification analyses were carried out by ethnicity, SOC, type of OA, Hardy--Weinberg equilibrium (HWE), genotype methods, and study quality. *P*\<0.05 was considered statistically significant. Multivariate ORs and corresponding 95% CIs between extreme levels of annualized case volume (highest vs lowest) were pooled using a random-effects model, accounting for clinical heterogeneity. Heterogeneity across studies was assessed by using the Q statistic with its *P* value and *I*^2^ statistic \[[@B18],[@B19]\]. Pooled ORs and 95% CIs were calculated in our meta-analysis which was performed using the following genetic models: (1) allele, (2) recessive, (3) homozygous, (4) heterozygous, and (5) dominant. The power of this meta-analysis was calculated with a significant value of 0.05 \[[@B20]\]. Two reviewers independently performed the extraction of data and assessed the study quality according to Newcastle--Ottawa scale (NOS) \[[@B21]\]. All disagreements were discussed and resolved with consensus. We tested HWE in controls by a Pearson's χ2 test (available in: <http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The data analyses were conducted with Stata 11.0 software (StataCorp, College Station, TX, U.S.A.). Potential publication bias was assessed by Begg's and Egger's linear regression test \[[@B22]\]. *P*\<0.05 was considered to indicate statistically significant. We performed sensitivity analysis by omitting each study in turn to determine the effect on the test of heterogeneity and evaluated the stability of the overall results.

Results {#sec3}
=======

Characteristics of the included studies {#sec3-1}
---------------------------------------

A total of 127 citations were derived after incipient search. Forty-one citations were removed due to duplication. Of the 86 remaining citations, 70 were excluded after reading titles and abstracts. Sixteen citations were selected for further full-text review. Three investigated other SNPs of *SMAD3* gene; two citations did not provide detailed genotyping data and four were not case--control study. Eventually, we identified seven eligible citations (5344 cases and 9080 controls) containing eleven studies \[[@B11]\]. Selection for qualified studies was presented in [Figure 1](#F1){ref-type="fig"}. The characteristics of included studies are summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The NOS of all included studies ranged from 5 to 7 stars, suggesting that these studies were of high methodological quality.

![Selection for eligible citations included in this meta-analysis](bsr-38-bsr20180380-g1){#F1}

###### Characteristics of included studies

  Author                    Year   Nationality    Type      Number of cases/controls   Genotype method
  ------------------------- ------ -------------- --------- -------------------------- ------------------
  Sharma, 2017 \[[@B11]\]   2017   India          Knee OA   450/458                    PCR­RFLP
  Su, 2015 \[[@B12]\]       2015   China          Knee OA   545/468                    PCR-RFLP
  Xiao, 2015 \[[@B13]\]     2015   China          TMJOA     114/126                    PCR
  Jiang, 2013 \[[@B14]\]    2013   China          Knee OA   102/220                    PCR-RFLP
  Jiang, 2013 \[[@B14]\]    2013   China          Hand OA   111/220                    PCR-RFLP
  Ana, 2010 \[[@B15]\]      2010   U.K.           Knee OA   1936/1253                  KASPar chemistry
  Ana, 2010 \[[@B15]\]      2010   U.K.           Hip OA    1193/1253                  KASPar chemistry
  Ana, 2010 \[[@B15]\]      2010   U.K./Estonia   Knee OA   492/1804                   KASPar chemistry
  Ana, 2010 \[[@B15]\]      2010   U.K./Estonia   Hip OA    95/1804                    KASPar chemistry
  Zhong, 2018 \[[@B16]\]    2018   China          Hip OA    500/1080                   TaqMan
  Zhang, 2018 \[[@B17]\]    2018   China          Knee OA   346/394                    MALDI-TOF MS

Abbreviations: OA, osteoarthritis; TMJOA, temporomandibular joint osteoarthritis.

###### Characteristics of included studies

  Author, year              SOC   Ethnicity    Case   Control   NOS   HWE                                               
  ------------------------- ----- ------------ ------ --------- ----- ------ ------ ----- ----- ----- ------ ------ --- -----
  Sharma, 2017 \[[@B11]\]   HB    Asians       165    131       154   439    461    158   198   102   402    514    5   NO
  Su, 2015 \[[@B12]\]       HB    Asians       142    274       129   532    558    116   228   124   476    460    6   YES
  Xiao, 2015 \[[@B13]\]     HB    Asians       31     53        30    113    115    44    67    15    97     155    7   YES
  Jiang, 2013 \[[@B14]\]    PB    Asians       22     68        12    92     112    114   83    23    129    311    6   YES
  Jiang, 2013 \[[@B14]\]    PB    Asians       25     73        13    99     123    114   83    23    129    311    6   YES
  Ana, 2010 \[[@B15]\]      HB    Caucasians   251    682       463   1608   1184   281   625   347   1319   1187   6   YES
  Ana, 2010 \[[@B15]\]      HB    Caucasians   219    584       390   1364   1022   281   625   347   1319   1187   6   YES
  Ana, 2010 \[[@B15]\]      PB    Caucasians   94     242       156   554    430    421   896   487   1870   1738   6   YES
  Ana, 2010 \[[@B15]\]      PB    Caucasians   18     47        30    107    83     421   896   487   1870   1738   6   YES
  Zhang, 2018 \[[@B16]\]    PB    Asians       10     200       290   780    220    20    610   450   1510   650    7   YES
  Zhang, 2018 \[[@B17]\]    HB    Asians       82     173       91    355    337    81    202   111   424    364    7   YES

Meta-analysis of *SMAD3* gene rs12901499 polymorphism {#sec3-2}
-----------------------------------------------------

In the general analysis, we found that *SMAD3* gene rs12901499 polymorphism increased OA risk (G vs A: OR and 95%CI, 1.26(1.12, 1.42), *P*\<0.001; GG vs AA: OR and 95%CI, 1.39(1.15, 1.67), *P*=0.001; GG + GA vs AA: OR and 95%CI, 1.34(1.07, 1.68), *P*=0.010; GG vs GA+AA: OR and 95%CI, 1.32(1.11, 1.56), *P*=0.001 [Table 3](#T3){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). And we did not obtain any different conclusion after eliminating Su et al.'s study \[[@B12]\] that does not meet the HWE. Stratification analyses were conducted according to ethnicity (G vs A: Asians, OR and 95%CI, 1.34(1.07, 1.69), *P*=0.012; Caucasians, OR and 95%CI, 1.21(1.13, 1.29), *P*\<0.001, [Figure 3](#F3){ref-type="fig"}), SOC, type of OA ([Figure 4](#F4){ref-type="fig"}), HWE, genotype methods, and study quality ([Table 4](#T4){ref-type="table"}).

![Forest plot shows odds ratio for the associations between rs12901499 polymorphism and OA risk (GG vs AA)](bsr-38-bsr20180380-g2){#F2}

![Stratification analysis by ethnicity shows odds ratio for the association between rs12901499 polymorphism and OA risk (GG vs AA)](bsr-38-bsr20180380-g3){#F3}

![Stratification analysis by type of OA shows odds ratio for the association between rs12901499 polymorphism and OA risk (GG vs GA + AA)](bsr-38-bsr20180380-g4){#F4}

###### Meta-analysis of association between *SMAD3* rs12901499 polymorphism and OA

  Comparison      OR (95%CI)         *P*-value   *P* for heterogeneity   *I*^2^ (%)   Model
  --------------- ------------------ ----------- ----------------------- ------------ --------
  G vs A          1.26(1.12, 1.42)   \<0.001     \<0.001                 75.8         Random
  GG vs AA        1.39(1.15, 1.67)   0.001       0.011                   56.2         Random
  GG + GA vs AA   1.34(1.07, 1.68)   0.010       \<0.001                 79.9         Random
  GG vs GA + AA   1.32(1.11, 1.56)   0.001       \<0.001                 71.6         Random
  GA vs AA        1.25(0.96, 1.63)   0.101       \<0.001                 84.0         Random

###### Summary of the subgroup analyses in this meta-analysis

  Comparison      Category           Category           Studies   OR (95% CI)            *P*-value
  --------------- ------------------ ------------------ --------- ---------------------- -------------
  G vs A          Ethnicity          **Asians**         **7**     **1.34(1.07, 1.69)**   **0.012**
                                     **Caucasians**     **4**     **1.21(1.13, 1.29)**   **\<0.001**
                  SOC                HB                 6         1.13(0.99, 1.28)       0.053
                                     PB                 5         1.49(1.22, 1.81)       \<0.001
                  Type               Knee OA            6         1.16(0.99, 1.35)       0.054
                                     TMJOA              1         1.57(1.09, 2.26)       0.015
                                     Hand OA            1         1.94(1.39, 2.71)       \<0.001
                                     **Hip OA**         **3**     **1.30(1.10, 1.55)**   **0.002**
                  HWE                Yes                1         1.22(1.01, 1.46)       0.037
                                     No                 10        1.27(1.12, 1.44)       \<0.001
                  Genotype methods   PCR-RFLP           4         1.40(0.99, 1.98)       0.056
                                     PCR                1         1.57(1.09, 2.26)       0.015
                                     KASPar chemistry   4         1.21(1.13, 1.29)       \<0.001
                                     Taqman             1         1.53(1.28, 1.82)       \<0.001
                                     MALDI-TOF MS       1         0.90(0.74, 1.11)       0.335
                  Study quality      Medium             8         1.25(1.11, 1.41)       \<0.001
                                     High               3         1.28(0.87, 1.88)       0.025
  GG vs AA        Ethnicity          Asians             7         1.44(0.99, 2.09)       0.059
                                     **Caucasians**     **4**     **1.46(1.28, 1.67)**   **\<0.001**
                  SOC                HB                 6         1.28(0.99, 1.65)       0.055
                                     PB                 5         1.56(1.24, 1.96)       \<0.001
                  Type               Knee OA            6         1.26(0.98, 1.63)       0.074
                                     TMJOA              1         2.84(1.31, 6.14)       0.008
                                     Hand OA            1         2.58(1.15, 5.77)       0.021
                                     **Hip OA**         **3**     **1.43(1.16, 1.76)**   **0.001**
                  HWE                Yes                1         1.45(1.04, 2.01)       0.030
                                     No                 10        1.39(1.12, 1.72)       0.002
                  Genotype methods   PCR-RFLP           4         1.53(0.93, 2.54)       0.097
                                     PCR                1         2.84(1.31, 6.14)       0.008
                                     KASPar chemistry   4         1.46(1.28, 1.67)       \<0.001
                                     Taqman             1         1.29(0.59, 2.79)       0.520
                                     MALDI-TOF MS       1         0.81(0.54, 1.22)       0.318
                  Study quality      Medium             8         1.42(1.19, 1.68)       \<0.001
                                     High               3         1.36(0.62, 2.88)       0.416
  GG + GA vs AA   Ethnicity          Asians             7         1.42(0.91, 2.22)       0.119
                                     **Caucasians**     **4**     **1.30(1.16, 1.46)**   **\<0.001**
                  SOC                HB                 6         1.10(0.92, 1.30)       0.304
                                     PB                 5         1.88(1.09, 3.25)       0.023
                  Type               Knee OA            6         1.23(0.92, 1.64)       0.164
                                     TMJOA              1         1.44(0.83, 2.49)       0.198
                                     Hand OA            1         3.70(2.20, 6.21)       \<0.001
                                     **Hip OA**         **3**     **1.26(1.06, 1.51)**   **0.011**
                  HWE                Yes                1         0.91(0.69, 1.19)       0.495
                                     No                 10        1.41(1.11, 1.79)       0.005
                  Genotype methods   PCR-RFLP           4         1.81(0.89, 3.66)       0.101
                                     PCR                1         1.44(0.83, 2.49)       0.198
                                     KASPar chemistry   4         1.30(1.16, 1.46)       \<0.001
                                     Taqman             1         0.92(0.43, 1.99)       0.841
                                     MALDI-TOF MS       1         0.83(0.59, 1.18)       0.304
                  Study quality      Medium             8         1.46(1.12, 1.89)       0.005
                                     High               3         0.99(0.71, 1.40)       0.975
  GG vs GA + AA   Ethnicity          Asians             7         1.37(0.97, 1.92)       0.071
                                     **Caucasians**     **4**     **1.27(1.15, 1.41)**   **\<0.001**
                  SOC                HB                 6         1.27(1.01, 1.59)       0.037
                                     PB                 5         1.41(1.09, 1.83)       0.010
                  Type               Knee OA            6         1.19(0.97, 1.47)       0.102
                                     TMJOA              1         2.64(1.34, 5.22)       0.005
                                     Hand OA            1         1.14(0.55, 2.34)       0.729
                                     **Hip OA**         **3**     **1.48(1.07, 2.03)**   **0.016**
                  HWE                Yes                1         1.82(1.35, 2.44)       \<0.001
                                     No                 10        1.27(1.07, 1.51)       0.007
                  Genotype methods   PCR-RFLP           4         1.21(0.76, 1.90)       0.420
                                     PCR                1         2.64(1.34, 5.22)       0.005
                                     KASPar chemistry   4         1.27(1.15, 1.41)       \<0.001
                                     Taqman             1         1.93(1.56, 2.40)       \<0.001
                                     MALDI-TOF MS       1         0.91(0.66, 1.26)       0.568
                  Study quality      Medium             8         1.25(1.09, 1.44)       0.001
                                     High               3         1.60(0.88, 2.92)       0.122
  GA vs AA        Ethnicity          Asians             7         1.30(0.76, 2.21)       0.335
                                     **Caucasians**     **4**     **1.21(1.07, 1.37)**   **0.002**
                  SOC                HB                 6         0.99(0.80, 1.22)       0.898
                                     PB                 5         1.78(0.94, 3.39)       0.078
                  Type               Knee OA            6         1.16(0.82, 1.65)       0.391
                                     TMJOA              1         1.12(0.63, 2.01)       0.698
                                     Hand OA            1         4.01(2.35, 6.85)       \<0.001
                                     Hip OA             3         1.14(0.91, 1.44)       0.249
                  HWE                Yes                1         0.63(0.46, 0.86)       0.004
                                     No                 10        1.34(1.04, 1.74)       0.025
                  Genotype methods   PCR-RFLP           4         1.75(0.73, 4.19)       0.206
                                     PCR                1         1.12(0.63, 2.01)       0.698
                                     KASPar chemistry   4         1.21(1.07, 1.37)       0.002
                                     Taqman             1         0.66(0.30, 1.42)       0.286
                                     MALDI-TOF MS       1         0.85(0.59, 1.22)       0.373
                  Study quality      Medium             8         1.40(1.02, 1.92)       0.038
                                     High               3         0.88(0.66, 1.17)       0.366

Abbreviations: HB, hospital-based controls; PB, population-based controls; SOC, source of controls; TMJOA, temporomandibular joint osteoarthritis. Medium quality: NOS = 5--6; High quality: NOS = 7.

We assessed sensitivity analysis by omitting each study once at a time in every genetic model for *SMAD3* gene rs12901499. The pooled ORs for the effects of the SNP on the risk for OA indicated that our data were stable and trustworthy. Both Egger's and Begg's tests were used to evaluated the publication bias of this meta-analysis. Our data revealed that there was no obvious publication bias for *SMAD3* gene rs12901499 ([Figure 5](#F5){ref-type="fig"}).

![Begg's tests between rs12901499 polymorphism and OA (GG vs AA)](bsr-38-bsr20180380-g5){#F5}

Discussion {#sec4}
==========

To our best knowledge, the present study is the first systematical meta-analysis regarding the association between *SMAD3* gene rs12901499 and OA susceptibility. TGF-β has anabolic effects on chondrocytes especially via the *SMAD3* genes signaling which promote the development and progression of OA \[[@B6]\]. Previous study reported the relationship between the genetic variants of TGF-β itself, TGF-β signaling, and OA \[[@B7]\]. In the signaling pathway of TGF-β, phosphorylated SMAD3 translocates to the nucleus to regulate gene expression and promote an anabolic phenotype in cartilage by forming a complex with SMAD4 \[[@B23]\]. Several previous studies reported the association between *SMAD3* gene rs12901499 polymorphism and risk of OA, but the results were inconsistent \[[@B11]\]. This meta-analysis summarized identified seven eligible citations (5344 cases and 9080 controls) containing 11 studies, and provided evidence that *SMAD3* gene rs12901499 polymorphism increased OA risk. Stratification analyses of ethnicity, SOC, type of OA, HWE, genotype methods, and study quality revealed that *SMAD3* gene rs12901499 polymorphism was also correlated with the increased risk of OA.

A single study could be underpowered because of sample size, diversity inheritance of the heterogeneous and complex OA etiology, different ethnicities, clinical heterogeneity, and so on. For instance, Sharma et al. \[[@B11]\] reported an increased association between *SMAD3* gene rs12901499 polymorphism and knee OA in an Indian population. Xiao et al. \[[@B13]\] found this SNP increased the risk of temporomandibular joint OA in a Chinese population. Liying et al. \[[@B14]\] reported this SNP increased both knee and hand OA in a Chinese population. And the study from Valdes et al. \[[@B15]\] indicated that *SMAD3* gene rs12901499 polymorphism is involved in increased risk of both hip and knee OA in European populations. Zhong et al. \[[@B16]\] found that *SMAD3* SNP rs12901499 GA genotype and G variant may increase the risk of hip OA in Chinese Han patients. Zhang et al. \[[@B17]\] confirmed that rs12901499 polymorphism in the *SMAD3* gene plays a protective role in the pathology of knee OA in a Chinese population. However, Su et al. \[[@B12]\] failed to obtain any relationship between *SMAD3* gene rs12901499 polymorphism and knee OA from a Chinese population. It is worthy of note that Valdes et al. \[[@B15]\] conducted eight separate studies (while we divided them into four groups depend on the SOC and type of OA), but three knee OA studies and two hip OA studies did not achieve statistical significance. The nature of OA-genetic susceptibility is likely to vary between different joint sites because the phenotype of osteoarthritis is site-specific. The proportion of genetic contribution of certain polymorphic locus to OA susceptibility may be influenced by other local environmental factors such as anatomical and biomechanical effects and by some joint-specific genetic factors most of which were postulated to be involved in cell signaling and signal transduction. In order to overcome the problem of conflicting results, we performed this comprehensive meta-analysis to evaluate the association of *SMAD3* gene rs12901499 polymorphism with OA risk.

Large sample and unbiased epidemiological studies of predisposition gene polymorphisms could provide insight into the association between candidate genes and diseases. When we dropped the study \[[@B11]\] which is not in agreement with HWE, the increased risk of OA was still found, suggesting the robustness of our findings. In addition, the power analysis indicated that this meta-analysis had a power of 99.9% to detect the effect of rs12901499 polymorphism on OA susceptibility with an OR of 1.26, also indicating that our data were robust. Some limitations encountered in this meta-analysis should be considered when these results are interpreted. First, the heterogeneity of this meta-analysis is high, so the data should be interpreted with caution. Second, due to limited data, we could not conduct further stratification analyses of other potential factors, such as age, gender, and body mass index (BMI). Third, our results were based on unadjusted estimates for confounding factors, which might have affected the final results. Fourth, we could not assess potential gene--gene and gene--environment interactions because of the lack of relevant data. Fifth, the conclusions of some stratification analyses about rs12901499 polymorphism should be interpreted with caution due to limited sample size. Sixth, we only can infer but cannot conclude that *SMAD3* gene rs12901499 polymorphisms are susceptibility loci of other types of OA, highlighting the necessity for the further investigation of more types of OA.

In conclusion, this meta-analysis confirms that *SMAD3* gene rs12901499 polymorphism increased OA risk. Stratification analysis of ethnicity found that rs12901499 polymorphism increased the risk of osteoarthritis among both Asians and Caucasians, subgroup analysis by type of osteoarthritis revealed that *smad family member 3* gene rs12901499 polymorphism was correlated with the increased risk of hip osteoarthritis, but not associated with knee osteoarthritis. Further, studies with large sample size and multiple OA type are necessary to validate whether *SMAD3* gene rs12901499 polymorphism contribute to OA susceptibility.
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